Bio:

Ronit Satchi-Fainaro, PhD, is a Full Professor of Pharmacology and Biomedical Engineering at Tel Aviv University, where she serves as Head of the Gray School of Medical Sciences and directs the Cancer Research & Nanomedicine Laboratory, and the Cancer Biology Research Center of Tel Aviv University and its 18-affiliated hospitals. She holds the Kurt and Herman Lion Chair in Nanosciences and Nanotechnologies and leads several interdisciplinary initiatives spanning drug delivery, cancer biology, and biomedical engineering.

Prof. Satchi-Fainaro received her BPharm from the Hebrew University of Jerusalem and her PhD in Polymer Chemistry and Cancer Nanomedicine from the University of London with Ruth Duncan. She completed postdoctoral training at Harvard Medical School and Boston Children's Hospital with Judah Folkman and has maintained long-standing academic ties with Harvard and the University of Lisbon as a Visiting Professor.

Her research focuses on understanding tumor–host interactions and translating these insights into targeted drug delivery systems, nanomedicines, and bioengineered platforms suitable for clinical testing. Her work has led to multiple clinical trials, including therapies for brain cancers and personalized treatment platforms based on 3D-bioprinted tumor models.

A Fellow of the CRS College of Fellows, former President of the Israeli CRS Chapter, and former Chair of the CRS International Committee, Prof. Satchi-Fainaro has authored over 170 publications, holds >100 patents, founded 3 companies, and is deeply committed to advancing the CRS mission through mentorship, translational science, and global collaboration.

Vision:

Ronit Satchi-Fainaro, PhD, is a Full Professor of Pharmacology and Biomedical Engineering at Tel Aviv University, where she serves as Head of the Gray School of Medical Sciences and directs the Cancer Research & Nanomedicine Laboratory, and the Cancer Biology Research Center of Tel Aviv University and its 18-affiliated hospitals. Her research bridges fundamental delivery science with clinical translation, advancing targeted drug-delivery systems, nanomedicines, and bioengineered platforms that have advanced into multiple clinical trials. She is a Fellow of the CRS College of Fellows and former President of the Israeli CRS Chapter.

If elected to the CRS Board of Directors, Prof. Satchi-Fainaro's vision is to further strengthen CRS as the leading global home for delivery science across academia, industry, and clinical translation. She is committed to fostering interdisciplinary collaboration that integrates engineering, biology, chemistry, and medicine, while promoting pathways that accelerate the translation of controlled-release technologies into patient impact. A key priority is expanding meaningful engagement among early-career investigators and trainees, and supporting diversity across scientific disciplines, geography, and career paths within CRS. She also aims to enhance industry–academia partnerships and global chapter activities, ensuring CRS continues to evolve with emerging technologies such as precision nanomedicine, biologics delivery, and data-driven design. Through these efforts, she seeks to support CRS's mission of advancing innovation, education, and global collaboration in delivery science.